Country - Finland
Summary - Direct Procurement For The Combination Preparation Of Nivolumab And Relatlimab (Opdualag® 240/ 80 Mg Inf.Cons., Atc Code L01Fy02) For The Period 1 April 2024–31 December 2025
Deadline - login to view
MT reference number - 81025603
Product classification - Pharmaceutical products
Address - Finland
Contact details - 565656565
Tender notice no. - 76454545
MT Ref Id - 81025603
Document Type - Tender Notices
Description - Description: The combination product of nivolumab and relatlimab is included in the national selection of services for the first-line treatment of advanced melanoma (which cannot be surgically removed or which has metastasized) in adults and adolesce nts aged 12 years or older with a PD-L1 expression level of tumor cells < 1%. According to the selection of services council, it is justified to target the treatment for patients according to the marketing authorization. Belonging to the service selection requires that the holder of the sales license and the buyer agree on a price lower than the public wholesale price.There is only one licensed combination product of nivolumab and relatlimab (Opd
Mt Ref Id - 81025603
Deadline - Nov 30, -0001
Similar Tenders :
Healthcare and Medicine